SEC Form 4
Arbutus Biopharma Corporation (ABUS) insider trading
No open-market ABUS insider purchases or sales were filed in the 12 months to Oct 26, 2026.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $0
- 0 filings
Who traded ABUS, and when
ABUS daily close from Oct 27, 2025 to Oct 26, 2026, between $3.67 and $5.22, last $4.22. No open-market insider purchases or sales were filed in this period.
No open-market insider purchases or sales were filed in the last 12 months.
Open-market trades
0 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | ||||||
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | |||||||
GET /stocks/filings/vX/form-4?tickers=ABUS&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ABUS"
],
"issuer_cik": "0001447028",
"owner_cik": "0001858748",
"accession_number": "0001447028-26-000059",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-01",
"issuer_name": "Arbutus Biopharma Corp",
"issuer_trading_symbol": "ABUS",
"owner_name": "Sawhney Roger",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-01",
"transaction_code": "D",
"equity_swap_involved": false,
"transaction_shares": 17142,
"transaction_price_per_share": 5,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 13683,
"transaction_value": 85710,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026."
}
]
},
{
"tickers": [
"ABUS"
],
"issuer_cik": "0001447028",
"owner_cik": "0002063445",
"accession_number": "0001447028-26-000060",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-01",
"issuer_name": "Arbutus Biopharma Corp",
"issuer_trading_symbol": "ABUS",
"owner_name": "Nguyen Tuan",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-01",
"transaction_code": "D",
"equity_swap_involved": false,
"transaction_shares": 48081,
"transaction_price_per_share": 5,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 111882,
"transaction_value": 240405,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 19 records
- Option exercises8 records
- Tax withholding4 records
- Grants and awards2 records
- Other5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has the Arbutus Biopharma Corporation's CEO sold stock?
No. Lindsay Androski (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ABUS’s insider data?
These are ABUS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ABUS insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ABUS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.